Tenascin-C As A New Marker For The Diagnosis And Treatment Monitoring Of Breast Cancer

Main Article Content

Enas Salah Shaker , M. S. Ali

Abstract

All over the world, the most frequent cancer and death cause among women is breast cancer. One of the most effective ways to avoid breast cancer is to diagnose it early. Tumor markers are the simplest and easiest methods for the clinical diagnosis of breast cancer, however, the currently used markers lack accurate specificity and sensitivity and their results are still controversial. Accordingly, the present study aims to investigate the possibility of using tenascin-c (TNC) protein as a new marker for the diagnosis in treatment monitoring of breast cancer. In this study, blood samples were collected from thirty age-matched untreated breast cancer patients, thirty hormonally treated breast cancer patients and thirty apparently healthy female subjects to serve as a control group. Serum levels of TNC, cancer antigen 15-3 (CA15-3), human epidermal growth factor 2 (HER2) and estradiol (E2) in all of the study subjects using enzyme linked immunosorbent assay (ELISA). Serum levels of TNC, CA15-3, HER2 and E2 were significantly increased in untreated breast cancer patients compared to the control group, however, their levels were significantly decreased in the hormonally treated breast cancer patients compared to the untreated patients. Tenascin-c may be used as a new marker for the diagnosis and treatment monitoring of breast cancer.

Article Details

Section
Articles